Clinical Efficacy of Enoxaparin Sequential Warfarin in the Treatment of Acute Pulmonary Embolism

BAI Yang

doi:10.14033/j.cnki.cfmr.2025.04.013

Abstract：Objective:To explore the clinical efficacy of Enoxaparin sequential Warfarin in the treatment of acute pulmonary embolism(APE).Method:A total of 80 patients with APE who were treated at Beijing Huairou Hospital from January 2022 to January 2024 were selected and randomly divided into control group(Enoxaparin)and observation group(Enoxaparin sequential Warfarin)by random number table method,40 cases in each group.The clinical efficacy,inflammatory factors,coagulation function,vascular endothelial function,lung function,and adverse reactions of the two groups were compared.Result:The total effective rate of the observation group was 95.0%,which was higher than 77.5%of the control group,and the difference was statistically significant(P<0.05).After treatment,the neutrophil to lymphocyte ratio(NLR),platelet to lymphocyte ratio(PLR),C-reactive protein(CRP),troponin I(TnI),B-type natriuretic peptide(BNP),D-dimer(D-D)decreased,nitric oxide(NO),forced expiratory volume at 1 second(FEV1),percentage of forced expiratory volume at one second(FEV1%pred),and percentage of forced vital capacity at 1 second(FVC%pred)all increased,the above indicators in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Sequential treatment with Enoxaparin and Warfarin in APE patients can reduce inflammatory factors,improve cardiac and lung function,promote endothelial function repair,and have high safety.